Quantbot Technologies LP Purchases New Holdings in Omnicell, Inc. $OMCL

Quantbot Technologies LP acquired a new stake in shares of Omnicell, Inc. (NASDAQ:OMCL) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 25,813 shares of the company’s stock, valued at approximately $786,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. WINTON GROUP Ltd acquired a new stake in Omnicell in the second quarter valued at $2,692,000. Advantage Alpha Capital Partners LP acquired a new position in Omnicell during the 2nd quarter worth $2,476,000. Assenagon Asset Management S.A. increased its position in shares of Omnicell by 1,316.2% in the 3rd quarter. Assenagon Asset Management S.A. now owns 140,675 shares of the company’s stock worth $4,284,000 after purchasing an additional 130,742 shares during the last quarter. Acadian Asset Management LLC raised its stake in shares of Omnicell by 33.9% in the 2nd quarter. Acadian Asset Management LLC now owns 168,519 shares of the company’s stock valued at $4,946,000 after purchasing an additional 42,676 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Omnicell in the 2nd quarter valued at about $282,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, EVP Corey J. Manley sold 6,106 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $49.90, for a total value of $304,689.40. Following the sale, the executive vice president owned 91,674 shares of the company’s stock, valued at approximately $4,574,532.60. This trade represents a 6.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 2.52% of the company’s stock.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $41.30 on Friday. The company has a market cap of $1.88 billion, a PE ratio of 1,032.76, a P/E/G ratio of 1.48 and a beta of 0.79. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.00. The firm has a 50-day simple moving average of $44.60 and a 200 day simple moving average of $38.31. The company has a quick ratio of 1.22, a current ratio of 1.43 and a debt-to-equity ratio of 0.14.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 5th. The company reported $0.40 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.47 by ($0.07). Omnicell had a return on equity of 3.00% and a net margin of 0.17%.The business had revenue of $313.98 million during the quarter, compared to the consensus estimate of $313.36 million. During the same period in the prior year, the business earned $0.60 EPS. The business’s revenue was up 2.3% on a year-over-year basis. Omnicell has set its Q1 2026 guidance at 0.260-0.360 EPS and its FY 2026 guidance at 1.650-1.850 EPS. On average, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OMCL shares. Weiss Ratings downgraded Omnicell from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday, March 2nd. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research note on Monday, February 9th. Wells Fargo & Company lifted their target price on Omnicell from $43.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Wall Street Zen downgraded Omnicell from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Finally, KeyCorp raised Omnicell from a “sector weight” rating to an “overweight” rating and set a $60.00 price target on the stock in a research report on Wednesday, January 7th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $54.50.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.